Teva and mAbxience strengthen global partnership to develop anti-PD-1 oncology biosimilar.

Teva Pharmaceuticals and mAbxience have strengthened their partnership with a new global licensing agreement to develop an anti-PD-1 oncology biosimilar. This initiative, marking their second collaboration, focuses on producing affordable, high-quality treatments for oncology. mAbxience will handle development and production in Spain and Argentina, while Teva will manage regulatory approvals and commercialization in the U.S. and Europe, aligning with Teva's growth strategy.

October 03, 2024
7 Articles